Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) Income towards Parent Company (2016 - 2025)

Acro Biomedical has reported Income towards Parent Company over the past 10 years, most recently at $42526.0 for Q4 2025.

  • Quarterly results put Income towards Parent Company at $42526.0 for Q4 2025, up 498.44% from a year ago — trailing twelve months through Dec 2025 was -$101146.0 (down 139.13% YoY), and the annual figure for FY2025 was -$101146.0, down 139.13%.
  • Income towards Parent Company for Q4 2025 was $42526.0 at Acro Biomedical, up from -$117809.0 in the prior quarter.
  • Over the last five years, Income towards Parent Company for ACBM hit a ceiling of $2.2 million in Q4 2021 and a floor of -$4.0 million in Q3 2022.
  • Median Income towards Parent Company over the past 5 years was -$88651.5 (2021), compared with a mean of -$1.3 million.
  • Biggest five-year swings in Income towards Parent Company: soared 3706.19% in 2021 and later crashed 6503.69% in 2022.
  • Acro Biomedical's Income towards Parent Company stood at $2.2 million in 2021, then crashed by 276.63% to -$3.9 million in 2022, then soared by 99.54% to -$18240.0 in 2023, then surged by 41.49% to -$10673.0 in 2024, then surged by 498.44% to $42526.0 in 2025.
  • The last three reported values for Income towards Parent Company were $42526.0 (Q4 2025), -$117809.0 (Q3 2025), and -$15562.0 (Q2 2025) per Business Quant data.